How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice

Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long‐term safety profile than CQ and is...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2023-03, Vol.53 (3), p.311-317
Main Authors: Fairley, Jessica L., Nikpour, Mandana, Mack, Heather G., Brosnan, Maria, Saracino, Amanda M., Pellegrini, Marc, Wicks, Ian P.
Format: Article
Language:English
Subjects:
adverse effects
Antimalarial agents
Antirheumatic Agents - adverse effects
Autoimmune diseases
cardiotoxicity
Chloroquine
Chloroquine - adverse effects
Connective tissue diseases
Connective tissues
COVID-19
COVID-19 Drug Treatment
Friends
Humans
Hydroxychloroquine
Hydroxychloroquine - adverse effects
Immunomodulation
Immunosuppression
Inflammation
Lupus Erythematosus, Systemic - drug therapy
retinopathy
Review
Rheumatoid arthritis
Rheumatology
safety
Systemic lupus erythematosus
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4448-386c745eea5369a834936a2528b3d6266cf62c9c2e07c65ed9115d93fe0e29753
cites cdi_FETCH-LOGICAL-c4448-386c745eea5369a834936a2528b3d6266cf62c9c2e07c65ed9115d93fe0e29753
container_end_page 317
container_issue 3
container_start_page 311
container_title Internal medicine journal
container_volume 53
creator Fairley, Jessica L.
Nikpour, Mandana
Mack, Heather G.
Brosnan, Maria
Saracino, Amanda M.
Pellegrini, Marc
Wicks, Ian P.
description Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long‐term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID‐19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice.
doi_str_mv 10.1111/imj.15908
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10947006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2791404392</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4448-386c745eea5369a834936a2528b3d6266cf62c9c2e07c65ed9115d93fe0e29753</originalsourceid><addsrcrecordid>eNp1kU1PwyAch4nR6Hw5-AUMiScP3aC8tJwWs_gyM-NFj4Yg_dexdGXSbrPfXubU6EEuQHjy8IMfQqeU9GkcAzef9alQJN9BPcq5SIRSfPdzzROiCDtAh00zI4RmTPF9dMCEkopS0kPPt36NW__uLHYNNjX2VYHL4KAuhvgSB1g5WGNf4nYKuDEltN1mN-2K4N87O6188G9LVwN2NbaVq501FV4EY1tn4RjtlaZq4ORrPkJP11ePo9tk8nAzHl1OEhsT5gnLpc24ADCCSWVyxhWTJhVp_sIKmUppS5laZVMgmZUCiphdFIqVQCBVmWBHaLj1LpYvcygs1G0wlV4ENzeh0944_fekdlP96leaEsUzQmQ0nH8ZNu-BptUzvwx1DK3TTFFOOFNppC62lA2-aQKUP1dQojdV6FiF_qwisme_M_2Q338fgcEWWLsKuv9Nenx_t1V-ABgzkyE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791404392</pqid></control><display><type>article</type><title>How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Fairley, Jessica L. ; Nikpour, Mandana ; Mack, Heather G. ; Brosnan, Maria ; Saracino, Amanda M. ; Pellegrini, Marc ; Wicks, Ian P.</creator><creatorcontrib>Fairley, Jessica L. ; Nikpour, Mandana ; Mack, Heather G. ; Brosnan, Maria ; Saracino, Amanda M. ; Pellegrini, Marc ; Wicks, Ian P.</creatorcontrib><description>Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long‐term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID‐19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice.</description><identifier>ISSN: 1444-0903</identifier><identifier>EISSN: 1445-5994</identifier><identifier>DOI: 10.1111/imj.15908</identifier><identifier>PMID: 35969110</identifier><language>eng</language><publisher>Melbourne: John Wiley &amp; Sons Australia, Ltd</publisher><subject>adverse effects ; Antimalarial agents ; Antirheumatic Agents - adverse effects ; Autoimmune diseases ; cardiotoxicity ; Chloroquine ; Chloroquine - adverse effects ; Connective tissue diseases ; Connective tissues ; COVID-19 ; COVID-19 Drug Treatment ; Friends ; Humans ; Hydroxychloroquine ; Hydroxychloroquine - adverse effects ; Immunomodulation ; Immunosuppression ; Inflammation ; Lupus Erythematosus, Systemic - drug therapy ; retinopathy ; Review ; Rheumatoid arthritis ; Rheumatology ; safety ; Systemic lupus erythematosus ; Toxicity</subject><ispartof>Internal medicine journal, 2023-03, Vol.53 (3), p.311-317</ispartof><rights>2022 The Authors. published by John Wiley &amp; Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.</rights><rights>2022 The Authors. Internal Medicine Journal published by John Wiley &amp; Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4448-386c745eea5369a834936a2528b3d6266cf62c9c2e07c65ed9115d93fe0e29753</citedby><cites>FETCH-LOGICAL-c4448-386c745eea5369a834936a2528b3d6266cf62c9c2e07c65ed9115d93fe0e29753</cites><orcidid>0000-0003-4140-2711</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35969110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fairley, Jessica L.</creatorcontrib><creatorcontrib>Nikpour, Mandana</creatorcontrib><creatorcontrib>Mack, Heather G.</creatorcontrib><creatorcontrib>Brosnan, Maria</creatorcontrib><creatorcontrib>Saracino, Amanda M.</creatorcontrib><creatorcontrib>Pellegrini, Marc</creatorcontrib><creatorcontrib>Wicks, Ian P.</creatorcontrib><title>How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice</title><title>Internal medicine journal</title><addtitle>Intern Med J</addtitle><description>Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long‐term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID‐19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice.</description><subject>adverse effects</subject><subject>Antimalarial agents</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Autoimmune diseases</subject><subject>cardiotoxicity</subject><subject>Chloroquine</subject><subject>Chloroquine - adverse effects</subject><subject>Connective tissue diseases</subject><subject>Connective tissues</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>Friends</subject><subject>Humans</subject><subject>Hydroxychloroquine</subject><subject>Hydroxychloroquine - adverse effects</subject><subject>Immunomodulation</subject><subject>Immunosuppression</subject><subject>Inflammation</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>retinopathy</subject><subject>Review</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>safety</subject><subject>Systemic lupus erythematosus</subject><subject>Toxicity</subject><issn>1444-0903</issn><issn>1445-5994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kU1PwyAch4nR6Hw5-AUMiScP3aC8tJwWs_gyM-NFj4Yg_dexdGXSbrPfXubU6EEuQHjy8IMfQqeU9GkcAzef9alQJN9BPcq5SIRSfPdzzROiCDtAh00zI4RmTPF9dMCEkopS0kPPt36NW__uLHYNNjX2VYHL4KAuhvgSB1g5WGNf4nYKuDEltN1mN-2K4N87O6188G9LVwN2NbaVq501FV4EY1tn4RjtlaZq4ORrPkJP11ePo9tk8nAzHl1OEhsT5gnLpc24ADCCSWVyxhWTJhVp_sIKmUppS5laZVMgmZUCiphdFIqVQCBVmWBHaLj1LpYvcygs1G0wlV4ENzeh0944_fekdlP96leaEsUzQmQ0nH8ZNu-BptUzvwx1DK3TTFFOOFNppC62lA2-aQKUP1dQojdV6FiF_qwisme_M_2Q338fgcEWWLsKuv9Nenx_t1V-ABgzkyE</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Fairley, Jessica L.</creator><creator>Nikpour, Mandana</creator><creator>Mack, Heather G.</creator><creator>Brosnan, Maria</creator><creator>Saracino, Amanda M.</creator><creator>Pellegrini, Marc</creator><creator>Wicks, Ian P.</creator><general>John Wiley &amp; Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4140-2711</orcidid></search><sort><creationdate>202303</creationdate><title>How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice</title><author>Fairley, Jessica L. ; Nikpour, Mandana ; Mack, Heather G. ; Brosnan, Maria ; Saracino, Amanda M. ; Pellegrini, Marc ; Wicks, Ian P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4448-386c745eea5369a834936a2528b3d6266cf62c9c2e07c65ed9115d93fe0e29753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>adverse effects</topic><topic>Antimalarial agents</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Autoimmune diseases</topic><topic>cardiotoxicity</topic><topic>Chloroquine</topic><topic>Chloroquine - adverse effects</topic><topic>Connective tissue diseases</topic><topic>Connective tissues</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>Friends</topic><topic>Humans</topic><topic>Hydroxychloroquine</topic><topic>Hydroxychloroquine - adverse effects</topic><topic>Immunomodulation</topic><topic>Immunosuppression</topic><topic>Inflammation</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>retinopathy</topic><topic>Review</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>safety</topic><topic>Systemic lupus erythematosus</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fairley, Jessica L.</creatorcontrib><creatorcontrib>Nikpour, Mandana</creatorcontrib><creatorcontrib>Mack, Heather G.</creatorcontrib><creatorcontrib>Brosnan, Maria</creatorcontrib><creatorcontrib>Saracino, Amanda M.</creatorcontrib><creatorcontrib>Pellegrini, Marc</creatorcontrib><creatorcontrib>Wicks, Ian P.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal medicine journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fairley, Jessica L.</au><au>Nikpour, Mandana</au><au>Mack, Heather G.</au><au>Brosnan, Maria</au><au>Saracino, Amanda M.</au><au>Pellegrini, Marc</au><au>Wicks, Ian P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice</atitle><jtitle>Internal medicine journal</jtitle><addtitle>Intern Med J</addtitle><date>2023-03</date><risdate>2023</risdate><volume>53</volume><issue>3</issue><spage>311</spage><epage>317</epage><pages>311-317</pages><issn>1444-0903</issn><eissn>1445-5994</eissn><abstract>Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long‐term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID‐19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice.</abstract><cop>Melbourne</cop><pub>John Wiley &amp; Sons Australia, Ltd</pub><pmid>35969110</pmid><doi>10.1111/imj.15908</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4140-2711</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1444-0903
ispartof Internal medicine journal, 2023-03, Vol.53 (3), p.311-317
issn 1444-0903
1445-5994
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10947006
source Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)
subjects adverse effects
Antimalarial agents
Antirheumatic Agents - adverse effects
Autoimmune diseases
cardiotoxicity
Chloroquine
Chloroquine - adverse effects
Connective tissue diseases
Connective tissues
COVID-19
COVID-19 Drug Treatment
Friends
Humans
Hydroxychloroquine
Hydroxychloroquine - adverse effects
Immunomodulation
Immunosuppression
Inflammation
Lupus Erythematosus, Systemic - drug therapy
retinopathy
Review
Rheumatoid arthritis
Rheumatology
safety
Systemic lupus erythematosus
Toxicity
title How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T07%3A38%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20toxic%20is%20an%20old%20friend?%20A%20review%20of%20the%20safety%20of%20hydroxychloroquine%20in%20clinical%20practice&rft.jtitle=Internal%20medicine%20journal&rft.au=Fairley,%20Jessica%20L.&rft.date=2023-03&rft.volume=53&rft.issue=3&rft.spage=311&rft.epage=317&rft.pages=311-317&rft.issn=1444-0903&rft.eissn=1445-5994&rft_id=info:doi/10.1111/imj.15908&rft_dat=%3Cproquest_pubme%3E2791404392%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4448-386c745eea5369a834936a2528b3d6266cf62c9c2e07c65ed9115d93fe0e29753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2791404392&rft_id=info:pmid/35969110&rfr_iscdi=true